Develops antibody drugs for life-threatening diseases.
Dec 2025Revenue $3.72B/yrExpenses $2.65B/yr
No trend
Figures by year
Is Genmab A/S profitable?
Yes. In the 12 months to Dec 2025, revenue was $3.72B and expenses $2.65B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.72B | $2.65B | $1.06B |
| Dec 2024 | $3.12B | $2.15B | $972M |
| Dec 2023 | $2.39B | $1.62B | $772M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.